| Literature DB >> 23319852 |
Mara B Greenberg1, Britta L Anderson, Jay Schulkin, Mary E Norton, Natali Aziz.
Abstract
Objective. To examine practice patterns for diagnosis and treatment of chorioamnionitis among US obstetricians. Study Design. We distributed a mail-based survey to members of the American College of Obstetricians and Gynecologists, querying demographics, practice setting, and chorioamnionitis management strategies. We performed univariable and multivariable analyses. Results. Of 500 surveys distributed, 53.8% were returned, and 212 met study criteria and were analyzed. Most respondents work in group practice (66.0%), perform >100 deliveries per year (60.0%), have been in practice >10 years (77.3%), and work in a nonuniversity setting (85.1%). Temperature plus one additional criterion (61.3%) was the most common diagnostic strategy. Over 25 different primary antibiotic regimens were reported, including use of a single agent by 30.0% of respondents. A wide range of postpartum antibiotic duration was reported from no postpartum treatment (34.5% after vaginal delivery, 11.3% after cesarean delivery) to 48 hours of postpartum treatment (24.7% after vaginal delivery, 32.1% after cesarean delivery). No practitioner characteristic was independently associated with diagnostic or therapeutic strategies in multivariable analysis. Conclusion. There is a wide variation in contemporary clinical practices for the management of chorioamnionitis. This may represent a dearth of level I evidence. Future prospective clinical trials may provide more evidence-based practice recommendations for diagnosis and treatment of chorioamnionitis.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23319852 PMCID: PMC3540735 DOI: 10.1155/2012/628362
Source DB: PubMed Journal: Infect Dis Obstet Gynecol ISSN: 1064-7449
Questions on diagnostic and treatment strategies.
| Describe your | |
| □ Elevated temperature alone | |
| □ Elevated temperature plus at least one additional sign or symptom | |
| □ Elevated temperature plus at least two additional signs or symptoms | |
| □ At least one sign or symptom alone without elevated temperature | |
| □ Other: | |
| What temperature is your threshold for diagnosing intrapartum chorioamnionitis? | |
| □ 37.8°C (100.0°F) | |
| □ 37.9°C (100.2°F) | |
| □ 38.0°C (100.4°F) | |
| □ 38.1°C (100.6°F) | |
| □ 38.2°C (100.8°F) | |
| □ Other: | |
| What strategies do you use to lower maternal temperature | |
| □ None | |
| □ IV fluid bolus | |
| □ PO hydration | |
| □ Tylenol or other antipyretics | |
| □ External cooling (application of ice or cool cloths) | |
| □ Other: | |
| If a patient has a fever alone, with no additional signs or symptoms of chorioamnionitis, is it likely that your decision to treat for chorioamnionitis would be influenced by whether the patient has an epidural? | |
| □ No | |
| □ Yes, I would be | |
| □ Yes, I would be | |
| Do you think your institution's policy on neonatal sepsis workup influences how frequently you diagnose maternal chorioamnionitis? | |
| □ No | |
| □ Yes, I am | |
| □ Yes, I am | |
| What is the | |
| □ Ampicillin | |
| □ Azithromycin | |
| □ Ancef (Cefazolin) | |
| □ Cefotetan | |
| □ Cefoxitin | |
| □ Clindamycin | |
| □ Ertapenem | |
| □ Gentamicin, daily dosing | |
| □ Gentamicin, TID dosing | |
| □ Metronidazole | |
| □ Unasyn (Ampicillin/sulbactam) | |
| □ Zosyn (Piperacillin/tazobactam) | |
| □ Ampicillin plus Gentamicin, daily dosing | |
| □ Ampicillin plus Gentamicin, TID dosing | |
| □ Ampicillin plus Gentamicin daily dosing plus Clindamycin | |
| □ Ampicillin plus Gentamicin TID dosing plus Clindamycin | |
| □ Other: | |
| What is the | |
| □ Same regimen as above | |
| □ Different regimen (please check all that apply): | |
| □ Ampicillin | |
| □ Azithromycin | |
| □ Ancef (Cefazolin) | |
| □ Cefotetan | |
| □ Cefoxitin | |
| □ Clindamycin | |
| □ Ertapenem | |
| □ Gentamicin, daily dosing | |
| □ Gentamicin, TID dosing | |
| □ Metronidazole | |
| □ Unasyn (Ampicillin/sulbactam) | |
| □ Zosyn (Piperacillin/tazobactam) | |
| □ Ampicillin plus Gentamicin, daily dosing | |
| □ Ampicillin plus Gentamicin, TID dosing | |
| □ Ampicillin plus Gentamicin daily dosing plus Clindamycin | |
| □ Ampicillin plus Gentamicin TID dosing plus Clindamycin | |
| □ Other: | |
| What is your strategy for postpartum treatment after a | |
| □ No additional antibiotics after delivery | |
| □ One additional dose of antibiotics after delivery | |
| □ Continue antibiotics for 24 hours after delivery | |
| □ Continue antibiotics for 48 hours after delivery | |
| □ Continue antibiotics for 24 hours after last fever | |
| □ Continue antibiotics for 48 hours after last fever | |
| □ Other: | |
| What is your strategy for postpartum treatment after a | |
| □ No additional antibiotics after delivery | |
| □ One additional dose of antibiotics after delivery | |
| □ Continue antibiotics for 24 hours after delivery | |
| □ Continue antibiotics for 48 hours after delivery | |
| □ Continue antibiotics for 24 hours after last fever | |
| □ Continue antibiotics for 48 hours after last fever | |
| □ Other: | |
| Do you treat with oral antibiotics after a patient has finished her postpartum course of IV antibiotics? | |
| □ Yes | |
| □ No |
*Responses were not limited to one of the choices listed but rather one or more than one antibiotic choice as needed to accurately reflect respondents' primary regimen.
Respondent characteristics.
| Respondent characteristics |
|
|---|---|
| Female | 103 (48.8%) |
| Male | 109 (51.2%) |
| Median age (IQR) | 51 (43–60) |
| Physician ethnicity | |
| Non-Hispanic White | 173 (82.0%) |
| Other | 38 (18.0%) |
| Number of deliveries annually | |
| <100 | 84 (40.0%) |
| >100 | 126 (60.0%) |
| Region of USa | |
| West | 46 (22.0%) |
| Midwest | 54 (25.8%) |
| South | 69 (33.0%) |
| Northeast | 38 (18.2%) |
| Practice location | |
| Suburban | 106 (50.2%) |
| Urban | 75 (35.5%) |
| Rural | 25 (11.8%) |
| Other | 5 (2.5%) |
| Predominant patient insurance type | |
| Private | 154 (73.3%) |
| Public | 55 (26.2%) |
| Uninsured | 1 (0.5%) |
| Predominant patient ethnicity | |
| Non-Hispanic White | 148 (70.8%) |
| Hispanic White | 32 (15.3%) |
| Other | 29 (13.9%) |
| Years in practice | |
| 0–5 | 5 (2.4%) |
| 6–10 | 43 (20.3%) |
| 11–15 | 43 (20.3%) |
| 16–20 | 25 (11.8%) |
| 21–25 | 34 (16.0%) |
| 26–30 | 27 (12.7%) |
| >30 | 35 (16.5%) |
| Practice setting | |
| Private or community | 174 (83.2%) |
| University or academic | 29 (13.9%) |
| Government | 5 (2.4%) |
| Other | 1 (0.5%) |
| Practice type | |
| Obgyn partnership/group | 140 (66.0%) |
| University/teaching institution | 26 (12.3%) |
| Solo practice | 38 (17.9%) |
| Laborist/hospitalist | 0 |
| Other | 8 (3.8%) |
aLocation of practice divided into four regions for purposes of analysis, according to the Centers for Disease Control and Prevention “Geographic Regions of the United States,” http://www.cdc.gov/.
Diagnostic and treatment strategies.
| Diagnostic strategies |
|
|---|---|
| Diagnosis based on | |
| Temperature alone | 56 (26.4%) |
| Temperature plus one additional criterion | 130 (61.3%) |
| Temperature plus two additional criteria | 16 (7.6%) |
| Other | 10 (4.7%) |
| Most common temperature threshold (degrees Centigrade) | |
| 37.9 | 6 (2.8%) |
| 38.0 | 154 (73.0%) |
| 38.1 | 23 (10.9%) |
| 38.2 | 18 (8.5%) |
| Other | 10 (4.7%) |
| Strategies used to lower temperature prior to diagnosis | |
| None | 65 (31.0%) |
| Intravenous fluids | 124 (59.0%) |
| Acetaminophen | 15 (7.1%) |
| Other | 6 (2.9%) |
| Influenced by presence of epidural in making diagnosis | |
| No | 124 (58.8%) |
| More likely to diagnose | 10 (4.7%) |
| Less likely to diagnose | 77 (36.5%) |
| Neonatal sepsis workup required for all chorioamnionitis diagnoses | |
| Yes | 170 (83.3%) |
| No | 34 (16.7%) |
| Influenced by neonatal sepsis workup policy in making diagnosis | |
| No | 191 (91.0%) |
| More likely to diagnose | 5 (2.3%) |
| Less likely to diagnose | 14 (6.7%) |
|
| |
| Treatment Strategies |
|
|
| |
| Primary treatment regimen | |
| Ampicillin and gentamicin ± additional agent | 135 (65.2%) |
| Single agent | 62 (30.0%) |
| Includes Gram-negative coverage | 177 (85.5%) |
| Does not include Gram-negative coverage | 30 (14.5%) |
| Change regimens for cesarean delivery | |
| Yes | 99 (46.9%) |
| No | 112 (53.1%) |
| Postpartum treatment strategy after vaginal delivery | |
| No additional antibiotics | 73 (34.6%) |
| 1 additional dose | 20 (9.5%) |
| 24 hours postpartum | 56 (26.5%) |
| 24 hours afebrile | 3 (1.4%) |
| 48 hours postpartum | 52 (24.7%) |
| 48 hours afebrile | 4 (1.9%) |
| Other | 3 (1.4%) |
| Postpartum treatment strategy after cesarean delivery | |
| No additional antibiotics | 24 (11.3%) |
| 1 additional dose | 15 (7.1%) |
| 24 hours postpartum | 70 (33.0%) |
| 24 hours afebrile | 17 (8.0%) |
| 48 hours postpartum | 68 (32.1%) |
| 48 hours afebrile | 16 (7.6%) |
| Other | 2 (0.9%) |
| Treat with oral antibiotics after intravenous course completed | |
| Yes | 34 (16.2%) |
| No | 176 (83.8%) |